Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?

The median survival time has been reported to vary between 5 and 8 years in low-grade (WHO grade 2) astrocytoma, and between 10 and 15 years for grade 2 oligodendroglioma. Targeted alpha therapy (TAT), using the modified peptide vector [(213)Bi]Bi/[(225)Ac]Ac-DOTA-substance P, has been developed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Krolicki, Leszek, Kunikowska, Jolanta, Cordier, Dominik, Slavova, Nedelina, Koziara, Henryk, Bruchertseifer, Frank, Maecke, Helmut R., Morgenstern, Alfred, Merlo, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650612/
https://www.ncbi.nlm.nih.gov/pubmed/37958683
http://dx.doi.org/10.3390/ijms242115701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650612/
https://www.ncbi.nlm.nih.gov/pubmed/37958683
http://dx.doi.org/10.3390/ijms242115701

Ejemplares similares